Hartman, R.

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial Commentary: Another piece of the Alzheimer's jigsaw

Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ

Cholinesterase and Neurodegenerative DiseasesDementia and Cognitive Impairment Research

Cited by 943

A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease

Farlow, M., Anand, R., Messina Jr, J., Hartman, R., & Veach, J. (2000) · European Neurology

Cholinesterase and Neurodegenerative DiseasesDementia and Cognitive Impairment Research

Cited by 332

Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal

Shiovitz, T. M., Welke, T. L., Tigel, P. D., Anand, R., Hartman, R. D., Sramek, J. J., Kurtz, N. M., & Cutler, N. R. (1996) · Schizophrenia Bulletin

Schizophrenia research and treatmentNeurotransmitter Receptor Influence on Behavior

Cited by 104